Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CHF6001 in Renal Impairment
NCT05431426Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tanimilast in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Area under the Curve of total plasma CHF6001 at 240 hours and Maximum Plasma Concentration at 240 hours. Started Jul 2022; status: completed.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05431426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431426.